06 4月 2021 by admin in UncategorizedComments Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
30 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters
26 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Pricing of Initial Public Offering
22 3月 2021 by admin in UncategorizedComments Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing
11 3月 2021 by admin in UncategorizedComments Adicet Reports Fourth Quarter and Full Year 2020 Financial results
10 3月 2021 by admin in UncategorizedComments Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B
